Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

24432 ARTÍCULOS , VIENDO DEL 1576 AL 1590

Targeting Biometals in Alzheimer's Disease with Metal Chelating Agents Including Coumarin Derivatives

Gucký A, Hamuľaková S.

CNS Drugs. 2024 Jul;38(7):507-532. doi: 10.1007/s40263-024-01093-0. Epub 2024 Jun 3.

Restoring the epigenome in Alzheimer's disease: advancing HDAC inhibitors as therapeutic agents

Pereira M, Cruz MT, Fortuna A, Bicker J.

Drug Discov Today. 2024 Jul;29(7):104052. doi: 10.1016/j.drudis.2024.104052. Epub 2024 Jun 1.

Focus of endothelial glycocalyx dysfunction in ischemic stroke and Alzheimer's disease: Possible intervention strategies

Balistreri CR, Di Giorgi L, Monastero R.

Ageing Res Rev. 2024 Aug;99:102362. doi: 10.1016/j.arr.2024.102362. Epub 2024 Jun 1.

Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit

Høilund-Carlsen PF, Alavi A, Barrio JR, Castellani RJ, Costa T, Herrup K, Kepp KP, Neve RL, Perry G, Revheim ME, Robakis NK, Sensi SL, Vissel B.

Ageing Res Rev. 2024 Aug;99:102348. doi: 10.1016/j.arr.2024.102348. Epub 2024 Jun 1.

Oxidative stress-mediated neuroinflammation in Alzheimer's disease

Firdous SM, Khan SA, Maity A.

Naunyn Schmiedebergs Arch Pharmacol. 2024 Nov;397(11):8189-8209. doi: 10.1007/s00210-024-03188-3. Epub 2024 Jun 4.

Distinctive contribution of two additional residues in protein aggregation of Aβ42 and Aβ40 isoforms

Im D, Choi TS.

BMB Rep. 2024 Jun;57(6):263-272. doi: 10.5483/BMBRep.2024-0044.

Case Studies 7A and 7B: Two Physician-Patients With Early Alzheimer's Disease and Differing Levels of Insight

Gettens Bourgea KM, Erkkinen M, Gale SA, McGinnis SM, Daffner KR, Silbersweig D, Schildkrout B.

J Neuropsychiatry Clin Neurosci. 2024 Summer;36(3):220-227. doi: 10.1176/appi.neuropsych.20230217. Epub 2024 Jun 5.

Unlocking hope: GSK-3 inhibitors and Wnt pathway activation in Alzheimer's therapy

Sai Varshini M, Aishwarya Reddy R, Thaggikuppe Krishnamurthy P.

J Drug Target. 2024 Sep;32(8):909-917. doi: 10.1080/1061186X.2024.2365263. Epub 2024 Jun 11.

Alzheimer's disease and drug delivery across the blood-brain barrier: approaches and challenges

Iqbal I, Saqib F, Mubarak Z, Latif MF, Wahid M, Nasir B, Shahzad H, Sharifi-Rad J, Mubarak MS.

Eur J Med Res. 2024 Jun 8;29(1):313. doi: 10.1186/s40001-024-01915-3.

The role of exosome-shuttled miRNAs in heavy metal-induced peripheral tissues and neuroinflammation in Alzheimer's disease

Dong Q, Fu H, Jiang H.

Biomed Pharmacother. 2024 Jul;176:116880. doi: 10.1016/j.biopha.2024.116880. Epub 2024 Jun 7.

The necroptosis cell death pathway drives neurodegeneration in Alzheimer's disease

Balusu S, De Strooper B.

Acta Neuropathol. 2024 Jun 9;147(1):96. doi: 10.1007/s00401-024-02747-5.

Differences in Cognitive Trajectories of Dementia: Comparison of Alzheimer's Disease Dementia and Dementia with Lewy Bodies in a Korean Patient Cohort

Cho BH, Kim H, Choi SM, Cho SH, Kim BC.

Dement Geriatr Cogn Disord. 2024;53(5):255-264. doi: 10.1159/000539743. Epub 2024 Jun 8.

Multi-target drugs for Alzheimer's disease

Turgutalp B, Kizil C.

Trends Pharmacol Sci. 2024 Jul;45(7):628-638. doi: 10.1016/j.tips.2024.05.005. Epub 2024 Jun 9.

Hippocampal transcriptome-wide association study and pathway analysis of mitochondrial solute carriers in Alzheimer's disease

Tian J, Jia K, Wang T, Guo L, Xuan Z, Michaelis EK, Swerdlow RH; Alzheimer’s Disease Neuroimaging Initiative; Du H.

Transl Psychiatry. 2024 Jun 10;14(1):250. doi: 10.1038/s41398-024-02958-0.

Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial)

Zeng L, Perin J, Gross AL, Shade D, Lanctôt KL, Lerner AJ, Mintzer JE, Brawman-Mintzer O, Padala PR, van Dyck CH, Porsteinsson AP, Craft S, Levey A, Herrmann N, Rosenberg PB.

Int J Geriatr Psychiatry. 2024 Jun;39(6):e6108. doi: 10.1002/gps.6108.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias